Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl₄-induced liver fibrosis.

ABSTRACT:

Background

Rifaximin is a poorly absorbed broad-spectrum antibiotic used for hepatic encephalopathy. Although increased Lactobacillaceae and decreased Bacteroidetes abundance are characteristic of hepatic encephalopathy, rifaximin does not dramatically alter the stool microbiota. As the antimicrobial effect of rifaximin increases by micellization with bile acids, we hypothesized that rifaximin alters the microbiota in the duodenum and jejunum, where the levels of bile acids are abundant.

Methods and results

Eight-week-old BALB/c mice were injected with carbon tetrachloride (CCl₄) intraperitoneally for 12 weeks to induce liver fibrosis. The mice were grouped into the control (n = 9), CCl₄ (n = 13), and rifaximin group in which mice were treated with rifa

SUBMITTER: Ikeuchi K 

PROVIDER: S-EPMC10029291 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature